Ligand Pharmaceuticals LGND Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $124.45M+3,187% | -$4.03M-108% | $52.15M+256% | -$33.36M-153% | ||
| $33.78M-4.2% | $35.24M-3.5% | $36.52M-29.1% | $51.53M+0.9% | ||
| $46.85M+14.0% | $41.09M+59.6% | $25.74M-57.3% | $60.29M+55.4% | ||
| -$22.68M-244% | $15.8M+235% | -$11.7M+43.6% | -$20.72M— | ||
| $1.27M+162% | $486K+102% | $240K-67.3% | $734K-95.6% | ||
| $21.74M— | —— | —— | —— | ||
| -$4.99M+48.1% | -$9.62M-183% | $11.58M+196% | -$12.06M— | ||
| $5.88M-57.7% | $13.9M— | —— | —— | ||
| —— | $4.96M— | —— | —— | ||
| —— | -$1.31M-412% | $419K+106% | -$6.48M— | ||
| —— | -$2.31M— | —— | -$1.58M-140% | ||
| $181K+302% | $45K— | —— | —— | ||
| $49.36M-49.1% | $97.05M+95.4% | $49.66M-64.0% | $137.85M+74.9% | ||
| $452K-75.2% | $1.82M-48.3% | $3.52M-80.4% | $17.92M+105% | ||
| —— | —— | $0-100% | $51.23M-71.7% | ||
| $159.58M-30.4% | $229.37M+54.2% | $148.77M-29.0% | $209.56M+35.9% | ||
| -$377.32M-163% | -$143.66M-1,130% | -$11.68M-107% | $170.91M— | ||
| $0-100% | $37.14M— | $0— | $0-100% | ||
| $27K+8.0% | $25K-44.4% | $45K-16.7% | $54K— | ||
| $9.6M+86.9% | $5.14M+13.0% | $4.55M-44.8% | $8.24M+36.9% | ||
| $15.53M+3,545% | $426K-55.1% | $949K— | $0— | ||
| $428.22M+341% | $97.14M— | —— | -$275.99M-94.5% | ||
| —— | -$1.17M— | —— | $0— | ||
| $102.62M+108% | $49.35M— | —— | $25.48M+185% | ||
| —— | —— | —— | —— | ||
| $321K+22.1% | $263K— | —— | $1.43M-52.8% | ||
| $7.8M-59.4% | $19.21M— | —— | $11.64M+213% | ||
| $4.96M+273% | $1.33M+1.0% | $1.32M— | —— | ||
| $1.27M+162% | $486K+102% | $240K-67.3% | $734K-95.6% | ||
| -$948K— | —— | $3.6M— | —— | ||
| $1.94M-8.7% | $2.13M+22.5% | $1.74M-68.6% | $5.52M— | ||
| $53.07M— | $0— | $0— | —— | ||
| —— | —— | —— | $28.54M+814% | ||
| -$22.68M-244% | $15.8M+235% | -$11.7M+43.6% | -$20.72M— | ||
| —— | -$2.31M-230% | $1.78M+213% | -$1.58M-140% | ||
| —— | —— | $265K— | —— | ||
| $8.62M+57.7% | $5.47M+519% | $883K+438% | $164K— | ||
| $1.02M+105% | -$20.01M-8,104% | $250K— | $0— | ||
| $0— | $0-100% | $5M— | $0— | ||
| $13.79M— | $0— | —— | $0— | ||
| $10.86M-39.0% | $17.82M-64.6% | $50.33M— | $0— | ||
| $3.85M+53.9% | $2.5M— | $0— | —— | ||
| $726.71M+221% | $226.38M+78.6% | $126.76M+147% | $51.23M-71.7% | ||
| —— | $7.12M— | $0— | $0— | ||
| $10.26M+38.1% | $7.43M+1,677% | $418K+354% | $92K— | ||
| $217.7M+557% | $33.13M-27.0% | $45.4M— | —— | ||
| $159.58M-30.4% | $229.37M+54.2% | $148.77M-29.0% | $209.56M+35.9% | ||
| $27K+8.0% | $25K-44.4% | $45K-16.7% | $54K— | ||
| $15.53M+3,545% | $426K-55.1% | $949K— | $0— | ||
| $0— | $0-100% | $347K— | $0— | ||
| $0— | $0-100% | $52K— | $0— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $1.77M— | —— | $0— | ||
| $181K+302% | $45K— | —— | —— | ||
| $48.91M-48.6% | $95.23M+105% | $46.34M-61.4% | $119.93M+71.2% | ||
| $48.91M-48.6% | $95.23M+105% | $46.34M-61.4% | $119.93M+71.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.